Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Cefazolin is an antibiotic recommended for infection prevention in total hip arthroplasty THA.
However, the dosing regimen necessary to achieve therapeutic concentrations in obese patients remains unclear. The aim of this study was to conduct a population analysis of cefazolin pharmacokinetics PK and assess whether cefazolin administration should be weight adapted in THA. A population PK study was conducted to quantify cefazolin exposure over time compared to the therapeutic concentration threshold. A 2-compartment model best fitted the data, and creatinine clearance determined interpatient variability in elimination clearance.
Our PK simulations using a mg cefazolin bolus showed that cefazolin concentrations remained above the threshold throughout surgery, regardless of weight or renal function. A mg cefazolin single injection without adaptation to weight or renal function and without intraoperative reinjection was efficient in maintaining therapeutic concentrations throughout surgery.
The optimal target concentration and necessary duration of its maintenance remain unclear. Deep prosthetic joint infections PJIs occur with an incidence ranging from 0.
They result in an altered quality of life for the patients 3 and increased medical costs for the healthcare system 3. Antimicrobial prophylaxis is the most effective strategy to prevent PJIs 4. Cefazolin, a first-generation cephalosporin, is currently administered for routine perioperative use to every patient undergoing THA.
